An observational study in Candida Infection, sponsored by Assiut University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by Assiut University · Observational
Candida spp are the fourth cause of nosocomial blood stream infections and had a 37% mortality rate within 30-day duration. Early diagnosis of Candida invasive infections reduces the mortality rate from 40% to 15% after therapy .There are several Candida species such as Candida albicans , Candida glabrata but C. albicans remains the most frequent species isolated there is an ongoing shift from C. albicans to non-albicans. Was reported by several countries. C. albicans, C. tropicalis, C. parapsilosis,C. krusei and C. glabrata are responsible for over 90% of cases of candidal infection .Several pathogenic virulence factors are encoded by C. albicans genes and assist the fungus to invade the host tissues leading to infections as the capacity of C. albicans to change from the budding yeast form to filamentous form .Many microbes, including yeasts, form biofilms as one of the major virulence factors. Candida infections often get therapeutic failure, mostly as a result of antifungal resistance that is caused by several mechanisms including biofilm production as biofilm- producing strains show significant increased resistance to antifungal drugs and host immunity.
Candida auris is an emergent pathogen that was first described in Japan. C. auris can be challenging to identify in the laboratory using conventional. Importantly, C. auris isolates are resistant to fluconazole and frequently show multidrug resistance.C. auris has a high capacity for dissemination via contaminated surfaces or horizontal patient-to-patient transfer, which is unusual in other Candida species.
132 studies on the registry are indexed under Candidiasis; 9 are open to participants now.
This study's planned enrollment of 300 is above the median of 162 across 39 observational studies indexed under Candidiasis.
Browse Candidiasis studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
patients admitted to hematology intensive care
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
oSuppressed general body immunity.
oSuppressed local body immunity as a result of trauma or invasive procedures.
oResistant to antibiotic therapy.
oNegative samples for bacterial examination and culture.
Critical life threatening infect
Exclusion Criteria:
Patients who received antifungal therapy within 3 days prior to sample collection.
To asses the prevalence of candida species as a cause of infection in patient in hematology intinsive care unit
Time frame: 1 year
To asses the prevalence of genes responsible for biofilm formation in different candida species
Time frame: 1 year
No study locations are listed for this record.
Start is estimated for Dec 2025; primary completion for Sep 2026, 9 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.